Search
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.
Ularitide
go.drugbank.com/drugs/DB05034InvestigationalUlaritide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF). … Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys.
Eprotirome
go.drugbank.com/drugs/DB05035InvestigationalEprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.
MVA3000
go.drugbank.com/drugs/DB05040ExperimentalMVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or … skin conditions such as eczema.
SGS518
go.drugbank.com/drugs/DB05042ExperimentalSGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).
Milveterol
go.drugbank.com/drugs/DB05043InvestigationalGSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Cannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
BZL101
go.drugbank.com/drugs/DB05051InvestigationalBZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
RG2417
go.drugbank.com/drugs/DB05055InvestigationalRG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential … Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy metabolism.
GFT14
go.drugbank.com/drugs/DB05061ExperimentalGFT14 is a new class of medicaction for treatment of cardiometabolic disease. … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.